Samidorphan mitigates olanzapine-induced weight gain and metabolic dysfunction in rats and non-human primates

, David J Eyerman, Mark S Todtenkopf, Reginald L Dean, Daniel R Deaver, Connie Sanchez & Mark Namchuk
Background:Olanzapine, regarded as one of the most efficacious antipsychotic medications for the treatment of schizophrenia, is associated with a high risk of weight gain and metabolic dysfunction. ALKS 3831, a clinical candidate for treatment of schizophrenia, is a combination of olanzapine and samidorphan, an opioid receptor antagonist. The addition of samidorphan is intended to mitigate weight gain and the metabolic dysregulation associated with the use of olanzapine.Methods:Non-clinical studies were conducted to assess the metabolic effects...
This data repository is not currently reporting usage information. For information on how your repository can submit usage information, please see our documentation.